09:13:49 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-06-11 Ordinarie utdelning SPAGO 0.00 SEK
2024-06-10 Årsstämma 2024
2024-05-02 Kvartalsrapport 2024-Q1
2024-02-07 Bokslutskommuniké 2023
2023-11-03 Kvartalsrapport 2023-Q3
2023-10-31 Extra Bolagsstämma 2023
2023-07-31 Kvartalsrapport 2023-Q2
2023-05-11 Ordinarie utdelning SPAGO 0.00 SEK
2023-05-10 Årsstämma 2023
2023-05-09 Kvartalsrapport 2023-Q1
2023-02-02 Bokslutskommuniké 2022
2022-11-08 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning SPAGO 0.00 SEK
2022-05-18 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-02 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning SPAGO 0.00 SEK
2021-05-05 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-02 Bokslutskommuniké 2020
2021-01-15 Extra Bolagsstämma 2021
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-24 Kvartalsrapport 2020-Q2
2020-05-29 Ordinarie utdelning SPAGO 0.00 SEK
2020-05-28 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-01-30 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-11-13 Extra Bolagsstämma 2019
2019-05-09 Ordinarie utdelning SPAGO 0.00 SEK
2019-05-08 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-01-30 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-05-17 Ordinarie utdelning SPAGO 0.00 SEK
2018-05-16 Årsstämma 2018
2018-04-25 Kvartalsrapport 2018-Q1
2018-02-14 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-09-22 Extra Bolagsstämma 2017
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-18 Ordinarie utdelning SPAGO 0.00 SEK
2017-05-17 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-14 Bokslutskommuniké 2016
2016-11-08 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-05-12 Ordinarie utdelning SPAGO 0.00 SEK
2016-05-11 Årsstämma 2016
2016-04-27 Kvartalsrapport 2016-Q1
2016-02-12 Bokslutskommuniké 2015
2015-11-12 Extra Bolagsstämma 2015
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-27 Kvartalsrapport 2015-Q2
2015-05-06 Ordinarie utdelning SPAGO 0.00 SEK
2015-05-05 Årsstämma 2015
2015-04-29 Kvartalsrapport 2015-Q1
2015-02-20 Bokslutskommuniké 2014
2014-11-14 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-04-30 Ordinarie utdelning SPAGO 0.00 SEK
2014-04-29 Årsstämma 2014
2014-04-29 Extra Bolagsstämma 2014
2014-04-29 Kvartalsrapport 2014-Q1
2014-02-21 Bokslutskommuniké 2013
2013-10-29 Kvartalsrapport 2013-Q3
2013-08-29 Kvartalsrapport 2013-Q2
2013-05-24 Kvartalsrapport 2013-Q1
2013-04-25 Årsstämma 2013
2013-02-22 Bokslutskommuniké 2012

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Spago Nanomedical är verksamt inom bioteknik. Bolaget utvecklar nanomedicin för diagnostik och behandling av livshotande sjukdomar. Bolagets huvudsakliga verksamhet är inriktad mot att utveckla ett cancerselektivt kontrastmedel för magnetisk resonanstomografi (MR), samt en produkt för radionuklidbehandling av cancer. Båda dessa projekt är baserade på egenutvecklade nanomaterial. Störst verksamhet återfinns inom den nordiska marknaden.
2023-11-07 08:47:00

The Board of Directors of Spago Nanomedical AB (publ) ("Spago Nanomedical" or the “Company") has prepared an EU Growth Prospectus (the "Prospectus") relating to the fully secured rights issue of units of approximately SEK 30.6 million before transaction costs (the “Rights Issue"), which was proposed by the Board of Directors on October 5, 2023, and resolved by the Extraordinary General Meeting held on October 31, 2023. The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.

Summary of the Rights Issue

  • Each existing share in the Company as of the record date on November 7, 2023, entitles the holder to seven (7) unit rights. Five (5) unit rights entitle the holder to subscribe for one (1) unit. Each unit consists of one (1) share and one (1) warrant of series TO12.
  • The subscription price in the Rights Issue is set at SEK 0.24 per unit, equivalent to SEK 0.24 per new share. The warrants are issued free of charge.
  • The subscription period runs from November 9, 2023, up to and including November 23, 2023.
  • Prior of the Rights Issue, the Company has received subscription commitments and entered into guarantee commitments totaling approximately SEK 30.6 million, equivalent to 100 percent of the Rights Issue.
  • The proceeds from the Rights Issue will enable, among other things, the ongoing development of Tumorad, including the inclusion of patients and the collection of initial results in the first clinical study with Tumorad in cancer patients.

"We see great potential shareholder value in advancing and accelerating the development of Tumorad, given a significant market potential and a great interest in the radionuclide therapy area from both investors and pharmaceutical companies. This capital raise gives us the conditions to focus fully on continuing to build value in Tumorad," says Mats Hansen, CEO of Spago Nanomedical.

Prospectus
The Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on November 7, 2023, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions, is available on the Company's, Hagberg & Aneborn Fondkommission AB's and Redeye AB's respective websites (www.spagonanomedical.se, www.hagberganeborn.se, www.redeye.se). The Prospectus will also be available on the Swedish Financial Supervisory Authority's website (www.fi.se). Subscription forms will be available on the Company's, Hagberg & Aneborn Fondkommission AB’s, and Redeye AB's respective websites.

Timetable for the Rights Issue

November 7, 2023Record date for the Rights Issue
November 9 – 20, 2023Trading in unit rights
November 9 – 23, 2023Subscription period
November 9, 2023 – Until the Rights Issue is registered with the Swedish Companies Registration OfficeTrading in paid subscribed units (Sw. “BTU”)
Around November 27, 2023Estimated publication of the outcome in the Rights Issue

Advisors
Redeye AB acts as financial advisor, and Advokatfirman Cederquist KB act as legal advisor to Spago Nanomedical in connection with the Rights Issue.